Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial

Zannad Faiez; Greenberg Barry; Cleland John G. F.; Gheorghiade Mihai; van Veldhuisen Dirk J.; Mehra Mandeep R.; Anker Stefan D.; Byra William M.; Fu Min; Mills Roger M.

首页> 外文期刊>European journal of heart failure: journal of the Working Group on Heart Failure of the European Society of Cardiology >Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial

【24h】

Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial

机译：一项随机，双盲，事件驱动，多中心研究的理由和设计，比较了利伐沙班和安慰剂口服利伐沙班在降低心衰和严重冠心病后的死亡，心肌梗塞或中风风险方面的功效和安全性心力衰竭加重：COMMANDER HF试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

AimsThrombin is a critical element of crosstalk between pathways contributing to worsening of established heart failure (HF). The aim of this study is to explore the efficacy and safety of rivaroxaban 2.5mg bid compared with placebo (with standard care) after an exacerbation of HF in patients with reduced ejection fraction (HF-rEF) and documented coronary artery disease.

机译：凝血酶是途径之间串扰的关键因素，导致已确立的心力衰竭（HF）恶化。这项研究的目的是探讨在射血分数降低（HF-rEF）和有冠状动脉疾病的患者加重HF后利伐沙班2.5mg bid与安慰剂（标准护理）相比的疗效和安全性。

著录项

来源
《European journal of heart failure: journal of the Working Group on Heart Failure of the European Society of Cardiology》 |2015年第7期|共8页
作者
Zannad Faiez; Greenberg Barry; Cleland John G. F.; Gheorghiade Mihai; van Veldhuisen Dirk J.; Mehra Mandeep R.; Anker Stefan D.; Byra William M.; Fu Min; Mills Roger M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心脏、血管（循环系）疾病;
关键词
rivaroxaban; thrombin; antithrombotic; heart failure; coronary artery disease;

机译：利伐沙班;凝血酶;抗血栓形成;心力衰竭;冠状动脉疾病;

相似文献

外文文献
中文文献
专利

1. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial [J] . Zannad Faiez, Greenberg Barry, Cleland John G. F., European journal of heart failure: journal of the Working Group on Heart Failure of the European Society of Cardiology . 2015,第7期

机译：一项随机，双盲，事件驱动，多中心研究的理由和设计，比较了利伐沙班和安慰剂口服利伐沙班在降低心衰和严重冠心病后的死亡，心肌梗塞或中风风险方面的功效和安全性心力衰竭加重：COMMANDER HF试验
2. A Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure: The COMMANDER HF study [J] . Greenberg Barry, Anker Stefan, Byra William M., Journal of cardiac failure . 2018,第11期

机译：一种随机研究，将Rivaroxaban与安慰剂在失效的心力衰竭事件中与心力衰竭和显着的冠状动脉疾病中的一种随机研究：指挥官HF研究
3. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy. [J] . Trachtenberg B, Velazquez DL, Williams AR, The American heart journal . 2011,第3期

机译：经心内膜注射自体人类细胞（骨髓或间充质）治疗继发于心肌梗塞的慢性缺血性左心室功能不全和心力衰竭（TAC-HFT）试验的原理和设计：一项随机，双盲，安慰剂对照的安全性研究和功效。
4. Rationale and design of a randomized double‐blind event‐driven multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial [O] . Faiez Zannad, Barry Greenberg, John G.F. Cleland, -1

机译：一项随机双盲事件驱动多中心研究的理由和设计该研究比较了口服利伐沙班与安慰剂在降低心衰和严重冠状动脉疾病患者死亡发生心肌梗塞或中风的风险方面的功效和安全性。心力衰竭加重：COMMANDER HF试验
5. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial [O] . Zannad, Faiez, Greenberg, Barry, Cleland, John G. F., 2015

机译：一项随机，双盲，事件驱动，多中心研究的理由和设计，比较了口服利伐沙班和安慰剂在降低心力衰竭和严重冠状动脉疾病后的死亡，心肌梗塞或中风风险方面的功效和安全性。心力衰竭加重：COMMANDER HF试验

摘要

著录项

相似文献

相关主题

期刊订阅